Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Recruiting

Phase 2

Golcadomide & RituximabGolcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Sponsor:

Mayo Clinic

Code:

NCT06834373

Conditions

Large B-Cell Lymphoma With IRF4 Rearrangement

Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma

Recurrent ALK-Positive Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type

Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Chimeric Antigen Receptor T-Cell Therapy

Computed Tomography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2025-04-04.